Background. Acute myeloid leukemia (AML) with the Philadelphia chromosome (Ph+ AML) is a rare and aggressive hematologic malignancy, occurring in approximately 1-2% of all AML cases. This subtype is characterized by the presence of the BCR-ABL1 fusion gene, which significantly impacts prognosis and treatment strategies. Differentiating Ph+ AML from chronic myeloid leukemia (CML) in blast crisis is critical due to distinct therapeutic requirements.

Case Summary. A 26-year-old Filipino male presented with a 9-day history of fever, headache, and sore throat. Initial examination revealed anemia, marked leukocytosis, and a peripheral blood smear showing predominantly blasts. Bone marrow biopsy confirmed AML with 62.1% blasts. Cytogenetic analysis identified the Philadelphia chromosome, and molecular testing revealed the BCR-ABL fusion gene. The patient received induction chemotherapy with hydroxyurea and cytarabine, followed by doxorubicin and cytarabine. Despite complications such as neutropenic enterocolitis, the patient achieved remission with a positive response to treatment.

Conclusion. Ph+ AML poses significant diagnostic and therapeutic challenges due to its aggressive nature and poor prognosis. Effective management requires accurate diagnosis, integration of tyrosine kinase inhibitors, and potential hematopoietic stem cell transplantation. Further research is needed to optimize treatment strategies and improve outcomes for this rare AML subtype. Personalized treatment and vigilant monitoring for relapse will enhance patient survival and quality of life.

Keywords. De Novo AML with BCR-ABL Mutation; BLAST crisis CML; Case Report; Ph+ AML

1. Abdulkarim, K., Girodon, F., Johansson, P., Maynadié, M., Kutti, J., Carli, P. M., Bovet, E., & Andréasson, B. (2009). AML transformation in 56 patients with Ph− MPD in two well defined populations. European journal of haematology, 82(2), 106-11
2. Ahmadmehrabi, K., Haque, A. R., Aleem, A., Griffiths, E. A., & Roloff, G. W. (2021). Targeted therapies for the evolving molecular landscape of acute myeloid leukemia. Cancers, 13(18), 4646.
3. Algeri, M., Merli, P., Locatelli, F., & Pagliara, D. (2021). The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. Journal of clinical medicine, 10(17), 3790.
4. Ali, R., Ozkalemkas, F., Ozkocaman, V., Yakut, T., Nazlioglu, H. O., Budak, F., Pekgoz, M., Korkmaz, S., Karkucak, M., & Ozcelik, T. (2009). Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. International journal of clinical oncology, 14, 545-550.
5. Calabretta, B., & Perrotti, D. (2004). The biology of CML blast crisis. blood, 103(11), 4010-4022.
6. Csanadi, M., Agh, T., Tordai, A., Webb, T., Jeyakumaran, D., Sengupta, N., Schain, F., & Mattsson, J. (2019). A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert review of hematology, 12(5), 311-323.
7. De Kouchkovsky, I., & Abdul-Hay, M. (2016). Acute myeloid leukemia: a comprehensive review and 2016 update. Blood cancer journal, 6(7), e441-e441.
8. DiNardo, C. D., & Cortes, J. E. (2016). Mutations in AML: prognostic and therapeutic implications. Hematology 2014, the American Society of Hematology Education Program Book, 2016(1), 348-355.
9. Greinix, H. T., Eikema, D.-J., Koster, L., Penack, O., Yakoub-Agha, I., Montoto, S., Chabannon, C., Styczynski, J., Nagler, A., & Robin, M. (2022). Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. haematologica, 107(5), 1054.
10. Hamadani, M., & Awan, F. T. (2010). Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematological Oncology, 28(1), 3-12.
11. Illangeswaran, R. S. S., Das, S., Paul, D. Z., Mathews, V., & Balasubramanian, P. (2019). A personalized approach to acute myeloid leukemia therapy: current options. Pharmacogenomics and personalized medicine, 167-179.
12. Kalita, A. (2014). Clinico-Hematological Study of Chronic Myeloid Leukemia Rajiv Gandhi University of Health Sciences (India)].
13. Kang, Z.-J., Liu, Y.-F., Xu, L.-Z., Long, Z.-J., Huang, D., Yang, Y., Liu, B., Feng, J.-X., Pan, Y.-J., & Yan, J.-S. (2016). The Philadelphia chromosome in leukemogenesis. Chinese journal of cancer, 35, 1-15.
14. Khemka, R., Gupta, M., & Jena, N. K. (2019). CML with megakaryocytic blast crisis: Report of 3 cases. Pathology & Oncology Research, 25, 1253-1258.
15. Lagunas-Rangel, F. A., Chávez-Valencia, V., Gómez-Guijosa, M. Á., & Cortes-Penagos, C. (2017). Acute myeloid leukemia—genetic alterations and their clinical prognosis. International Journal of Hematology-Oncology and Stem Cell Research, 11(4), 328.
16. Pemovska, T., Kontro, M., Yadav, B., Edgren, H., Eldfors, S., Szwajda, A., Almusa, H., Bespalov, M. M., Ellonen, P., & Elonen, E. (2013). Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer discovery, 3(12), 1416-1429.
17. Pfeifer, H., Wettner, C., Wassmann, B., Giagounidis, A., Stelljes, M., Dührsen, U., Schmalzing, M., Schaich, M., De Wit, M., & Ganser, A. (2012). Long term follow up of elderly patients with philadelphiapositive acute lymphoblastic leukaemia (PH+ ALL): Updated results of the GMALL elderly trials. haematologica, 97, 463.
18. Pullarkat, S. T., Vardiman, J. W., Slovak, M. L., Rao, D. S., Rao, N. P., Bedell, V., & Said, J. W. (2008). Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leukemia Research, 32(11), 1770-1775.
19. Redner, A., & Kessel, R. (2022). Acute myeloid leukemia. In Lanzkowsky's Manual of Pediatric Hematology and Oncology (pp. 439-458). Elsevier.
20. Saleh, K., Fernandez, A., & Pasquier, F. (2022). Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers, 14(7), 1805.
21. Sampaio, M. M., Santos, M. L. C., Marques, H. S., de Souza Gonçalves, V. L., Araújo, G. R. L., Lopes, L. W., Apolonio, J. S., Silva, C. S., de Sá Santos, L. K., & Cuzzuol, B. R. (2021). Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World journal of clinical oncology, 12(2), 69.
22. Senapati, J., Jabbour, E., Kantarjian, H., & Short, N. J. (2023). Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia, 37(1), 5-17.
23. Soupir, C. P., Vergilio, J.-A., Cin, P. D., Muzikansky, A., Kantarjian, H., Jones, D., & Hasserjian, R. P. (2007). Philadelphia chromosome–positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. American journal of clinical pathology, 127(4), 642-650.
24. Sun, Y., Wang, J., Jiang, Q., Xu, L., Liu, D., Zhang, X., Liu, K., & Huang, X. (2015). Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone marrow transplantation, 50(1), 20-25.
25. Tran, T. H., & Tasian, S. K. (2021). Has Ph-like ALL superseded Ph+ ALL as the least favorable subtype? Best Practice & Research Clinical Haematology, 34(4), 101331.
26. Tsirigotis, P., Byrne, M., Schmid, C., Baron, F., Ciceri, F., Esteve, J., Gorin, N., Giebel, S., Mohty, M., & Savani, B. (2016). Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone marrow transplantation, 51(11), 1431-1438.
27. Wang, L., Li, L., Chen, R., Huang, X., & Ye, X. (2021). Understanding and monitoring chronic myeloid leukemia blast crisis: how to better manage patients. Cancer Management and Research, 4987-5000.
28. Zhou, T., Medeiros, L. J., & Hu, S. (2018). Chronic myeloid leukemia: beyond BCR-ABL1. Current hematologic malignancy reports, 13, 435-445.